Ozempic and Pregnancy: Is Semaglutide Safe? The 2-Month Washout Rule (2026)

The short, careful answer: semaglutide (the active drug in Ozempic and Wegovy) is not recommended during pregnancy, and the FDA labels advise that if you become pregnant, it should be discontinued.^[1][2] Because semaglutide has a long half-life of about one week, the label also advises stopping it at least 2 months before a planned pregnancy so it has cleared your system before you conceive.^[1] The data picture behind this guidance is straightforward to state and important to understand: there is limited human data on semaglutide in pregnancy, while animal reproductive studies showed adverse effects on the developing fetus at clinically relevant exposures.^[1][2] None of this is cause for panic if you conceived while taking it — the labeled move is to stop and contact your provider, not to assume harm. This article explains exactly what the label says, the reasoning behind the 2-month washout, what to do if you got pregnant on it, breastfeeding, and the fertility context behind the "Ozempic babies" headlines. It is general education, not medical advice — pregnancy decisions belong with your OB-GYN or endocrinologist. See our Ozempic drug page and Ozempic side effects guide for the broader profile.

What the FDA label actually says

Both semaglutide labels address pregnancy directly in §8.1, and the bottom line is consistent: semaglutide is not recommended in pregnancy. The Ozempic label (the type-2-diabetes product) states that the limited available data are insufficient to determine a drug-associated risk of major birth defects or miscarriage, but that based on animal reproduction studies there may be potential risks to the fetus from exposure during pregnancy — and it advises that Ozempic should be discontinued in patients once pregnancy is recognized.^[1]

The Wegovy label (the chronic-weight-management product, same molecule at a higher dose) goes a step further in its framing: because weight loss offers no benefit during pregnancy and may cause fetal harm, semaglutide for weight management is not recommended, and it too should be discontinued when pregnancy is recognized.^[2] The distinction is logical — in type-2 diabetes there can be a competing concern (poorly controlled blood sugar carries its own risks to a pregnancy), whereas there is no reason to pursue intentional weight loss during pregnancy at all.

One important piece of nuance the diabetes label adds: poorly controlled diabetes in pregnancy carries real risks of its own to the pregnant person and the fetus (a recognized concern in obstetric care). That is not a reason to stay on semaglutide — it is a reason to have a plan, with your clinician, for keeping diabetes well controlled in pregnancy using treatments considered appropriate for use during pregnancy.^[1] Insulin, for example, is a mainstay of diabetes management in pregnancy; your clinician decides what fits you. The takeaway from the label is simple to remember: semaglutide is not the drug to be on while pregnant, and the plan to come off it (and to manage whatever it was treating) is a clinical one.

The 2-month washout before a planned pregnancy

If you are planning a pregnancy, the labels give a concrete timing rule. Because of semaglutide's long half-life of approximately one week, the FDA labeling advises discontinuing semaglutide at least 2 months before a planned pregnancy.^[1] This is the most actionable, frequently-searched fact in this whole topic — the so-called "2-month rule."

The reasoning is pharmacokinetic. A drug's half-life is the time it takes for the amount in your body to fall by half, and as a rule of thumb a drug is largely cleared after roughly four to five half-lives. With semaglutide's ~1-week half-life, that places near-complete clearance in the neighborhood of 5 weeks or so — and the label's ~2-month buffer adds a deliberate margin of safety on top, so that by the time you are trying to conceive (and through the earliest, most vulnerable weeks of fetal development, which can begin before a pregnancy is even detected) there is essentially no semaglutide on board.^[1] In practical terms: if you and your clinician decide you want to try to conceive, the plan is to stop semaglutide about two months ahead of starting to try, with a reliable contraception plan in place until then, and a plan for whatever the drug was managing.

This timing — like everything here — is something to map out with your OB-GYN or endocrinologist, who can fold in your blood-sugar control, your weight history, any other medications, and how long it has taken you to come off the medication smoothly.

Why — animal reproductive-toxicity findings and limited human data

The caution rests on two facts that pull in the same direction: the human data are limited, and the available animal data are concerning.

On the human side, there is not enough data from pregnant patients to establish whether semaglutide is associated with major birth defects, miscarriage, or adverse maternal or fetal outcomes — the label is explicit that the available information is insufficient to determine a drug-associated risk.^[1] An "insufficient data" status is not the same as a clean bill of health; it means the safety question has not been answered, and in pregnancy the default with an unanswered safety question is caution.

On the animal side, the labels report that in reproduction studies, administering semaglutide to pregnant animals during organogenesis caused adverse developmental effects — including embryofetal mortality, structural abnormalities, and growth alterations — at clinically relevant exposures.^[1][2] Animal findings do not automatically translate to humans, but in the absence of reassuring human data they carry real weight in how regulators and clinicians reason about risk. Together, "limited human data plus adverse animal reproductive findings" is precisely the combination that produces a "not recommended in pregnancy" label and the 2-month washout advice above.

If you conceived while taking it

First, the reassuring framing: discovering you are pregnant while on semaglutide is not, by itself, a reason to panic, and it is a situation clinicians see and manage. The "insufficient data" status above cuts both ways — it means harm has not been demonstrated either. What it does mean is that you should act, and act through your clinician.

The labeled guidance is direct: semaglutide should be discontinued once pregnancy is recognized, and you should contact your healthcare provider.^[1][2] Practically, that means:

• Stop the medication and contact your OB-GYN (and your prescriber). Don't wait for the next scheduled dose; reach out promptly so the next steps — including how to manage whatever the drug was treating — can be planned. If you have diabetes, stopping abruptly without a blood-sugar plan is its own risk, which is why this is a clinician conversation.^[1]
• Don't assume harm — and don't make any irreversible decision based on the medication alone. The human data are insufficient to establish a specific risk; your OB-GYN is the right person to discuss what this means for your individual pregnancy, including any monitoring they recommend.
• Ask about reporting to a pregnancy registry / surveillance. Manufacturers and regulators collect outcomes data on medication exposures in pregnancy; your clinician can advise whether and how to report, which also helps close the very data gap that drives the uncertainty here.^[2]

The single most useful sentence to carry away: stop it, and call your provider — not as an emergency-room dash, but as a prompt, deliberate step so a clinician who knows your history can guide the rest.

Breastfeeding on semaglutide

The lactation picture mirrors the pregnancy one: there are limited or no human data on the presence of semaglutide in human milk, its effects on a breastfed infant, or its effects on milk production.^[1][2] With that uncertainty, the labels frame breastfeeding as a clinical decision that weighs the developmental and health benefits of breastfeeding against the parent's need for the medication and any potential risk to the infant — in other words, there is no blanket "yes" or "no," and it is genuinely a case-by-case call.

Because semaglutide is a large peptide molecule, some clinicians reason about its likely transfer into milk and absorption by an infant differently than they would a small-molecule drug — but that is exactly the kind of individualized judgment your clinician is there to make, not something to decide from a web page. If you are breastfeeding or planning to, raise it specifically with your OB-GYN, pediatrician, or endocrinologist before starting or restarting semaglutide.

Fertility and the "Ozempic babies" context

You have likely seen headlines about so-called "Ozempic babies" — reports of unexpected pregnancies in people taking GLP-1 medications. It is worth being precise about what is and isn't being claimed here, because it is easy to overread.

There are two plausible, non-mysterious mechanisms behind the phenomenon, and neither makes semaglutide a fertility treatment:

• Weight loss can restore ovulation, especially in PCOS. In polycystic ovary syndrome (PCOS) and in obesity-related anovulation, meaningful weight loss can improve insulin resistance and help restore more regular ovulation and menstrual cycles — which can improve fertility. Since GLP-1 medications drive weight loss, a person who was not ovulating regularly may begin to, and may conceive. This is a downstream effect of weight loss, not a direct fertility action of the drug — a context point, not a treatment indication. GLP-1 medications are not FDA-approved to treat infertility, and using them to try to conceive is not their purpose.
• Reduced birth-control effectiveness. The other contributor is unintended pregnancy from contraception failing — covered in the next section — particularly with oral contraceptives around the GI upset and altered gastric emptying these drugs can cause. An "unexpected" pregnancy can simply be a pill that didn't work as expected.

The practical implication runs the opposite direction from the headlines: if you are taking semaglutide and do not want to become pregnant, you should be more attentive to reliable contraception, not less — because your fertility may have quietly improved even as the drug itself must be avoided in pregnancy. If you are trying to conceive, the plan is to come off semaglutide (with the ~2-month washout) and pursue fertility care through the appropriate clinician, not to rely on the medication.

Birth control and semaglutide

Because semaglutide is avoided in pregnancy and may coincide with improved fertility, effective contraception matters more, not less, while you are on it — and there are two efficacy considerations worth raising with your clinician.

• GI side effects can blunt the pill. Oral contraceptives rely on being absorbed; vomiting or significant diarrhea — both common, especially during semaglutide dose increases — can reduce how much of an oral contraceptive your body absorbs, theoretically lowering its protection. This is a general principle for any oral contraceptive paired with a drug that can cause GI upset.
• Delayed gastric emptying is a known interaction concern. GLP-1 medications slow how quickly the stomach empties, which can affect the absorption of co-administered oral medications. For combination injectable GLP-1/GIP products this has been addressed with specific contraceptive precautions in labeling; for semaglutide specifically, the practical move is to discuss your contraception with your prescriber rather than assume your current method is unaffected.

A common, clinician-discussed workaround is to consider a non-oral, highly reliable method (for example, an IUD, implant, or other long-acting reversible contraception) that does not depend on gastrointestinal absorption — but the right choice is individual. The point for this article is narrow and important: if avoiding pregnancy is your goal while on semaglutide, confirm your contraception plan with your provider, especially across the weeks when GI side effects are heaviest.

Key guidance at a glance

Bottom line — plan with your clinician

• Semaglutide (Ozempic, Wegovy) is not recommended during pregnancy. If you become pregnant, the labels say to discontinue it and contact your provider.^[1][2]
• Planning a pregnancy? Stop it at least ~2 months ahead. The drug's ~1-week half-life means it needs roughly two months (with a safety margin) to clear before you try to conceive.^[1]
• The caution is driven by limited human data plus adverse animal reproductive findings — an unanswered safety question, which in pregnancy defaults to avoidance.^[1][2]
• Conceived on it? Stop, call your provider — don't panic. Harm is not established; the right move is prompt clinical guidance, not a solo decision.^[1][2]
• Breastfeeding and contraception are both individual, clinician-led decisions. Limited lactation data; GI effects can affect the pill — so confirm your plan with your clinician.^[1][2]
• "Ozempic babies" reflect weight-loss-driven fertility gains and contraception slips — not a fertility drug. If you don't want to conceive, be more attentive to reliable birth control while on semaglutide.

If you are weighing whether and how to use semaglutide under proper medical supervision — including timing it around family planning — a legitimate provider will take a full history, discuss contraception and pregnancy intentions, and follow up. Compare the best semaglutide providers, or read our reviews of Found and Ro, and see the Ozempic and Wegovy drug pages plus our Ozempic side effects guide for the full profile. Pregnancy and family-planning decisions belong with your OB-GYN or endocrinologist — this page is general education to bring to that conversation, not a substitute for it.